title: Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study.
abstract: A better understanding of the association between diabetes and pancreatic cancer (PC) may inform prevention and/or early detection strategies. Metformin has been associated with reduced risk of certain cancers, including PC, in some observational clinical studies. We assessed whether metformin use was associated with PC risk among those with type 2 diabetes (DM2), and whether metformin use modulated the association between DM2 and risk of PC. In total, 536 PC cases and 869 frequency-matched controls were recruited predominantly from University of California San Francisco medical clinics from 2006 to 2011. Eligible participants completed direct interviews using a structured risk factor questionnaire. The association between metformin use and PC risk was assessed using propensity score-weighted unconditional logistic regression methods in analyses restricted to diabetics and adjusted multivariable logistic models in the total study population. Ever use of metformin was not associated with PC risk in analyses restricted to DM2 (N = 170) participants (adjusted OR: 1.01, 95% CI: 0.61-1.68). In the total study population (N = 1,405) using nondiabetics as the referent group, PC risk was inversely associated with diabetes duration (ptrend  < 0.001). Further, when DM2 participants were grouped by ever/never use of metformin and compared with nondiabetics, metformin use did not affect the association between DM2 and PC risk (never users: OR: 1.44, 95% CI: 0.78-2.67; ever users: OR: 1.19, 95% CI: 0.72-1.99). Results from our clinic-based case-control study suggest that metformin use is not associated with PC risk among those with DM2 and does not alter the association between DM2 and PC risk.
authors.affiliation: Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, CA.
authors.forename: Evan J
authors.initials: EJ
authors.lastname: Walker
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Ko
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Holly
authors.forename: Paige M
authors.initials: PM
authors.lastname: Bracci
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D016015:Logistic Models; D008297:Male; D008687:Metformin / Q000009:adverse effects*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000209:etiology*; D012306:Risk
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin
keywords: cancer risk; metformin; pancreatic adenocarcinoma; type 2 diabetes
references.citation: PLoS One. 2012;7(3):e33411
references.pmid: 22448244
references.citation: BMC Cancer. 2011 Jan 18;11:20
references.pmid: 21241523
references.citation: Endocr Rev. 2007 Feb;28(1):20-47
references.pmid: 16931767
references.citation: Stat Med. 1998 Oct 15;17(19):2265-81
references.pmid: 9802183
references.citation: J Surg Oncol. 2013 Jan;107(1):1-7
references.pmid: 22589078
references.citation: PLoS One. 2013 Aug 02;8(8):e71583
references.pmid: 23936520
references.citation: JAMA. 2001 Aug 22-29;286(8):921-9
references.pmid: 11509056
references.citation: Gastroenterology. 2008 Apr;134(4):981-7
references.pmid: 18395079
references.citation: World J Gastroenterol. 2008 Dec 21;14(47):7192-8
references.pmid: 19084933
references.citation: Stat Med. 2004 Oct 15;23(19):2937-60
references.pmid: 15351954
references.citation: BMC Cancer. 2011 Apr 15;11:138
references.pmid: 21496267
references.citation: Cancer Epidemiol. 2013 Jun;37(3):207-18
references.pmid: 23352629
references.citation: Diabetologia. 2012 Mar;55(3):654-65
references.pmid: 22127412
references.citation: Eur J Cancer. 2011 Sep;47(13):1928-37
references.pmid: 21458985
references.citation: Am J Gastroenterol. 2012 Apr;107(4):620-6
references.pmid: 22290402
references.citation: Nutr Cancer. 2013;65(1):157-64
references.pmid: 23368926
references.citation: Cancer Causes Control. 2011 Feb;22(2):189-97
references.pmid: 21104117
references.citation: J Pers Soc Psychol. 1986 Dec;51(6):1173-82
references.pmid: 3806354
references.citation: Gastroenterology. 2009 Aug;137(2):482-8
references.pmid: 19375425
references.citation: Br J Cancer. 2005 Jun 6;92(11):2076-83
references.pmid: 15886696
references.citation: N Engl J Med. 1994 Jul 14;331(2):81-4
references.pmid: 8208269
references.citation: Diabetologia. 2010 Sep;53(9):1838-45
references.pmid: 20532476
references.citation: Cancer Res. 1995 May 15;55(10):2007-11
references.pmid: 7743492
references.citation: Cell Metab. 2010 May 5;11(5):390-401
references.pmid: 20444419
references.citation: N Engl J Med. 1993 May 20;328(20):1433-7
references.pmid: 8479461
references.citation: JAMA. 2005 Jan 12;293(2):194-202
references.pmid: 15644546
references.citation: Med Oncol. 2012 Jun;29(2):1314-27
references.pmid: 21301998
references.citation: Mol Endocrinol. 1992 Dec;6(12):2219-28
references.pmid: 1283442
references.citation: Cancer Causes Control. 2012 Dec;23(12):1929-37
references.pmid: 23015286
references.citation: J Natl Cancer Inst. 1997 Mar 19;89(6):442-6
references.pmid: 9091646
references.citation: Arch Intern Med. 1996 Oct 28;156(19):2255-60
references.pmid: 8885826
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2093-7
references.pmid: 16172215
references.citation: Diabetes Care. 2011 Apr;34(4):923-9
references.pmid: 21447664
references.citation: Gastroenterology. 2008 Jan;134(1):95-101
references.pmid: 18061176
references.citation: N Engl J Med. 2010 Apr 29;362(17):1605-17
references.pmid: 20427809
references.citation: Diabetes Care. 2011 Sep;34(9):1965-71
references.pmid: 21775752
references.citation: Diabetologia. 2009 Sep;52(9):1766-77
references.pmid: 19572116
references.citation: Clin Cancer Res. 2012 May 15;18(10):2723-5
references.pmid: 22465829
references.citation: Nature. 2010 Oct 28;467(7319):1114-7
references.pmid: 20981102
references.citation: J Natl Cancer Inst. 2013 Jul 17;105(14):1027-35
references.pmid: 23847240
references.citation: Ann Oncol. 2012 Apr;23(4):843-52
references.pmid: 21890910
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087